Silexion Therapeutics Corp (SLXN): Nasdaq/NYSE listing notice — Silexion Therapeutics appeals Nasdaq delisting; hearing set for June 26, 2025

Silexion Therapeutics Corp

Received Nasdaq delisting notice on May 22 for MVLS <$50M and MVPHS <$15M deficiencies.
Requested hearing on May 28, 2025, staying delisting; hearing scheduled June 26, 2025.
Intends to apply to transfer listing to Nasdaq Capital Market under Equity Standard requiring ≥$2.5M shareholders' equity.
No assurance of success; securities continue trading on Nasdaq under SLXN and SLXNW.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Silexion Therapeutics Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A), 5450(b)(2)(C), 5810(c)(3)(C)

Exact text from the filing

Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C), which require a company such as ours whose securities are listed on the Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “ MVLS ”) of $50,000,000 and a minimum Market Value of Publicly Held Shares (an “ MVPHS ”) of $15,000,000 for continued listing on the Nasdaq Global Market.

View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Silexion Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001178913-25-002045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.